Adage Capital Management focuses on managing S&a;P 500 assets predominantly for endowments and foundations.
Business Model:
Revenue: $3.7M
Employees: 11-50
Address: 200 Clarendon Street
City: Boston
State: MA
Zip: 02116
Country: US
Adage Capital Management is a Boston-based $8.9B Money Management firm focused on managing S&a;P 500 assets predominantly for Endowments and Foundations such as Harvard University, Northwestern University, Dartmouth College, the American Red Cross and the Getty Foundation. Adage and its predecessor, the Select Equity Group at the Harvard Management Company, has outperformed the S&a;P index in each of the last 15 years by an average of 3.5%. The fund is run by Phill Gross, who prior to founding Adage, was a Healthcare and Retail analyst, equity research director and partner at the Harvard Management Company for 18 years..
Contact Phone:
+16178672800
Contact Email:
Announced Date | Company | Transaction | Money Raised |
---|---|---|---|
3/2018 | Prevail Therapeutics | Series A | 75M |
7/2022 | Annexon Biosciences | Post-IPO Equity | 0 |
11/2020 | MedAvail | Series E | 0 |
2/2021 | HemoShear Therapeutics | Series A | 40M |
1/2021 | Werewolf Therapeutics | Series B | 0 |
11/2018 | Cabaletta Bio | Series A | 38M |
4/2014 | Epirus Biopharmaceuticals | Series B | 36M |
10/2013 | Calithera Biosciences | Series D | 35M |
2/2022 | Energy Vault | Post-IPO Equity | 150M |
10/2011 | Puma Biotechnology | Post-IPO Equity | 55M |
10/2021 | Pyramid Biosciences | Series B | 0 |
12/2012 | Ultragenyx Pharmaceutical | Series B | 75M |
10/2018 | Tanium | Private Equity Round | 200M |
4/2021 | Arcellx | Series C | - |
6/2020 | C4 Therapeutics | Series B | 150M |
4/2017 | SteadyMed Therapeutics | Post-IPO Equity | 0 |
9/2017 | Engage Therapeutics | Series A | 23.6M |
10/2021 | Scout Bio | Series B | 0 |
7/2021 | Gopuff | Series H | 0 |
5/2021 | SiMa.ai | Series B | 80M |
4/2021 | Arch Oncology | Series C | 0 |
9/2019 | GitLab | Series E | 268M |
4/2014 | Vapotherm | Series B | 0 |
8/2020 | Pyramid Biosciences | Venture Round | 0 |
12/2022 | Karyopharm Therapeutics | Post-IPO Equity | 0 |
12/2017 | Aptinyx | Series B | 70M |
5/2020 | Amplyx Pharmaceuticals | Series C | 0 |
5/2020 | Pulmonx | Equity | 66M |
4/2021 | HawkEye 360 | Series C | 0 |
4/2014 | Nexvet | Series B | 31.5M |
5/2021 | Larimar Therapeutics | Post-IPO Equity | 0 |
3/2019 | Scout Bio | Series B | 20M |
6/2018 | Precision BioSciences | Series B | 0 |
6/2020 | Poseida Therapeutics | Series D | 110M |
4/2021 | Antios Therapeutics | Series B | 0 |
2/2020 | Flywire | Series E | 120M |
3/2014 | Lumena Pharmaceuticals | Series B | 45M |
9/2022 | Ventyx Biosciences | Post-IPO Equity | 0 |
2/2021 | Silence Therapeutics | Post-IPO Equity | 0 |
8/2021 | Pepgen | Venture Round | 0 |
7/2020 | Cerevel Therapeutics | Post-IPO Equity | 0 |
4/2021 | Stem | Post-IPO Equity | 225M |
12/2015 | Welldoc | Series B | 0 |
9/2018 | Galera Therapeutics | Series C | 70M |
1/2019 | Cabaletta Bio | Series B | 0 |
11/2020 | Ambrx | Private Equity Round | 200M |
6/2021 | ImaginAb | Growth | 12.8M |
2/2005 | FibroGen | Venture Round | 0 |
6/2015 | Advanced Accelerator Applications | Venture Round | 25.7M |
5/2021 | PathAI | Series C | 0 |
10/2014 | MedAvail | Series C | 0 |
7/2018 | MedAvail | Series D | 0 |
3/2013 | PTC Therapeutics | Private Equity Round | 60M |
3/2021 | Flywire | Series F | 60M |
12/2018 | Annexon Biosciences | Series C | 75M |
3/2019 | Prevail Therapeutics | Series B | 50M |
3/2015 | Aimmune Therapeutics | Series B | 80M |
3/2022 | Menlo Micro | Series C | 0 |
9/2015 | AveXis | Series D | 65M |
3/2015 | Collegium Pharmaceutical | Private Equity Round | 0 |
4/2022 | Harness | Series D | 0 |
11/2021 | Antios Therapeutics | Series B | 0 |
5/2021 | Forter | Series F | 300M |
11/2015 | Vapotherm | Series C | 0 |
7/2008 | Portola Pharmaceuticals | Series C | 60.1M |
6/2021 | Goat Group | Series F | 195M |
3/2021 | Aura Biosciences | Venture Round | 0 |
7/2015 | Protagonist Therapeutics | Series C | 0 |
7/2020 | Praxis Precision Medicines | Series C | 0 |
4/2008 | Concert Pharmaceuticals | Series C | 0 |
3/2021 | Caribou Biosciences | Series C | 115M |
11/2021 | HawkEye 360 | Series D | 0 |
9/2017 | ImaginAb | Venture Round | 0 |
3/2014 | ZS Pharma | Series D | 0 |
7/2015 | Vapotherm | Series C | 0 |
11/2015 | AppDynamics | Series F | 0 |
8/2021 | Beckley Psytech | Series B | 0 |
9/2020 | Eledon Pharmaceuticals | Post-IPO Equity | 108M |
2/2015 | Advaxis | Post-IPO Equity | 0 |
12/2021 | connectRN | Venture Round | 0 |
11/2022 | BioAtla | Post-IPO Equity | 0 |
4/2014 | Adverum Biotechnologies | Series B | 55M |
11/2022 | Abeona Therapeutics | Post-IPO Equity | 0 |
10/2021 | CinCor Pharma | Series B | 0 |
4/2021 | Theseus Pharmaceuticals | Series B | 0 |
3/2021 | Rapid Micro Biosystems | Private Equity Round | 0 |
7/2020 | Annexon Biosciences | Series C | 100M |
9/2020 | Flame Biosciences | Venture Round | 100M |
7/2022 | Annexon Biosciences | Post-IPO Equity | 0 |
4/2022 | Harness | Series D | 0 |
3/2022 | Menlo Micro | Series C | 0 |
2/2022 | Energy Vault | Post-IPO Equity | 0 |
12/2021 | connectRN | Venture Round | 0 |
11/2021 | HawkEye 360 | Series D | 0 |
11/2021 | Antios Therapeutics | Series B | 0 |
10/2021 | Scout Bio | Series B | 0 |
10/2021 | Pyramid Biosciences | Series B | 0 |
10/2021 | CinCor Pharma | Series B | 0 |
Name | Price |
---|
Name | Size | Announced Date |
---|